drugset / Trial / NCT01283581

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

NCT01283581

Phase 2 Completed 256 enrolled Melinta Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical trials

Timeline

Start
2011-01
Primary completion
2011-11
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Delafloxacin Small molecule 300 mg Intravenous
Comparator Linezolid Other / unclassified 600 mg Intravenous
Comparator Vancomycin Other / unclassified 15 mg/kg Intravenous